Zydus Lifesciences Ltd., the innovation-driven Indian healthcare company with a strong international footprint, has introduced its latest biosimilar, ‘Zyrifa’, a Denosumab-based therapy designed to improve access to advanced bone health treatments. Denosumab is a widely used monoclonal antibody prescribed for osteoporosis and for preventing skeletal complications in patients suffering from cancers that spread to the bones.
With Zyrifa now available at an MRP of ₹12,495, Zydus aims to make a critical therapy more accessible to patients dealing with bone metastases arising from breast, prostate, lung, kidney, thyroid, myeloma, head and neck cancers, as well as other solid tumours. Bone metastases typically indicate an advanced stage of cancer and remain one of the most painful, debilitating, and life-altering complications for patients.
When cancers reach the bones, patients often experience persistent pain, fractures, spinal cord compression, and severe mobility limitations that chip away at their independence and quality of life. These complications most frequently affect the axial skeleton, especially the spine, ribs, and pelvis, making day-to-day movement extremely difficult.
Large population studies have shown just how common skeletal involvement becomes as cancers progress. In advanced breast and prostate cancer, bone metastases affect nearly half to more than two-thirds of all patients. Lung, kidney, thyroid, and melanoma cases also show significant bone involvement, with about 15 to 40 percent eventually developing skeletal metastases as the disease advances. These numbers highlight the need for affordable and effective medications such as Denosumab biosimilars, which can slow down bone loss, reduce fracture risk, and ease the overall burden of cancer-related skeletal complications.
